Deutsche Bank AG Has $107,000 Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

Deutsche Bank AG boosted its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 26.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,157 shares of the company’s stock after buying an additional 8,946 shares during the period. Deutsche Bank AG owned approximately 0.06% of Nkarta worth $107,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new position in Nkarta during the fourth quarter worth $37,000. Catalina Capital Group LLC grew its position in Nkarta by 57.5% in the 4th quarter. Catalina Capital Group LLC now owns 18,818 shares of the company’s stock worth $47,000 after purchasing an additional 6,867 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in Nkarta in the 4th quarter worth $31,000. Thrivent Financial for Lutherans bought a new position in shares of Nkarta during the 4th quarter worth about $258,000. Finally, American Century Companies Inc. raised its position in shares of Nkarta by 8.8% during the fourth quarter. American Century Companies Inc. now owns 90,952 shares of the company’s stock valued at $226,000 after buying an additional 7,378 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Trading Up 2.3%

NASDAQ NKTX opened at $1.77 on Wednesday. Nkarta, Inc. has a 1-year low of $1.31 and a 1-year high of $8.23. The stock’s 50 day moving average is $1.82 and its two-hundred day moving average is $2.09. The company has a market capitalization of $125.60 million, a price-to-earnings ratio of -0.94 and a beta of 0.81.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01. On average, analysts predict that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Nkarta in a research report on Thursday, March 27th. William Blair reiterated a “market perform” rating on shares of Nkarta in a research report on Thursday, May 15th. Stifel Nicolaus lowered their price objective on Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 27th. Finally, Needham & Company LLC reduced their target price on Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, May 15th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Nkarta presently has a consensus rating of “Buy” and an average price target of $14.67.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.